Leticia Garcia-Montoya
Overview
Explore the profile of Leticia Garcia-Montoya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
173
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Siddle H, Wilson M, Nam J, Garcia-Montoya L, Duquenne L, Mankia K, et al.
Rheumatology (Oxford)
. 2024 Dec;
PMID: 39656784
Objectives: We aimed to develop a prediction model identifying people presenting to primary care with musculoskeletal symptoms likely to be anti-CCP positive and therefore at risk of developing rheumatoid arthritis...
2.
Di Matteo A, Mankia K, Garcia-Montoya L, Sharrack S, Duquenne L, Nam J, et al.
RMD Open
. 2024 Apr;
10(2).
PMID: 38599655
Objectives: To investigate the role of third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in predicting progression to inflammatory arthritis (IA) in individuals with new musculoskeletal (MSK) symptoms and a negative second-generation...
3.
Garcia-Montoya L, Villota-Eraso C, Md Yusof M, Vital E, Emery P
Lancet Rheumatol
. 2024 Jan;
2(8):e497-e509.
PMID: 38273611
B-cell depletion therapy is an effective option for the treatment of rheumatoid arthritis but often does not result in complete B-cell depletion. Complete B-cell depletion after rituximab treatment is associated...
4.
Garcia-Montoya L, Kang J, Duquenne L, Di Matteo A, Nam J, Harnden K, et al.
Lancet Rheumatol
. 2024 Jan;
6(2):e72-e80.
PMID: 38267105
Background: Subclinical synovitis occurs in a third of individuals at risk of rheumatoid arthritis. The objective of this study was to assess the reversibility of subclinical synovitis in individuals at...
5.
Di Matteo A, De Lorenzis E, Duquenne L, Nam J, Garcia-Montoya L, Harnden K, et al.
Rheumatology (Oxford)
. 2023 Nov;
63(8):2213-2221.
PMID: 37934127
Objectives: To investigate, in anti-CCP antibody-positive individuals with musculoskeletal symptoms but no clinical synovitis (CCP+ at-risk), the additional value of US for the prediction of inflammatory arthritis. Furthermore, to define...
6.
Duquenne L, Hensor E, Wilson M, Garcia-Montoya L, Nam J, Wu J, et al.
Ann Intern Med
. 2023 Jul;
176(8):1027-1036.
PMID: 37523695
Background: Inflammatory arthritis (IA) is an immune-related condition defined by the presence of clinical synovitis. Its most common form is rheumatoid arthritis. Objective: To develop scores for predicting IA in...
7.
Dubash S, Alabas O, Michelena X, Garcia-Montoya L, De Marco G, Merashli M, et al.
Rheumatol Adv Pract
. 2022 Mar;
5(3):rkab086.
PMID: 35284780
Objective: To evaluate the relationship between clinical examination/US synovitis in DMARD-naïve early PsA. Methods: Eligible patients underwent matched clinical/US 44-joint assessment for tender and/or swollen joints (TJ/SJ) and US synovitis...
8.
Garcia-Montoya L, Nam J, Duquenne L, Villota-Eraso C, Di Matteo A, Hartley C, et al.
Arthritis Res Ther
. 2022 Jan;
24(1):26.
PMID: 35042555
Background: Musculoskeletal (MSK) symptoms are among the commonest reasons for primary care assessments; however, few individuals will be diagnosed with an inflammatory arthritis (IA) within the following year. The purpose...
9.
Dubash S, Alabas O, Michelena X, Garcia-Montoya L, Wakefield R, Helliwell P, et al.
Ann Rheum Dis
. 2021 Dec;
81(4):490-495.
PMID: 34893470
Objective: To characterise the impact of dactylitis in disease-modifying antirheumatic drug (DMARD)-naive early psoriatic arthritis (PsA). Methods: Patients with early PsA meeting the classification criteria for PsA (CASPAR) were recruited....
10.
Di Matteo A, Duquenne L, Cipolletta E, Nam J, Garcia-Montoya L, Wakefield R, et al.
Rheumatology (Oxford)
. 2021 Dec;
61(8):3192-3200.
PMID: 34849610
Objectives: To investigate whether anti-CCP2-positive at-risk individuals with musculoskeletal (MSK) symptoms but without clinical synovitis (CCP2+ at-risk) develop US subclinical synovitis before inflammatory arthritis and if US subclinical synovitis can...